BioCentury This WeekWUSA9
About The Show Meet The Team Program Archive Become a Sponsor
UPDATE FLASH PLAYER AND EXPERIENCE THE NEW BCTV SHOW GUIDE

Mobile Banner Image


      HOME     ABOUT BIOCENTURY     WHY BCTV?     PRESS RELEASES    FREE CONTENT    LINK TO BCTV    CONTACT US   
Advertisement



BIOCENTURY EXTRA LATEST HEADLINES


   TOP STORY

NewLink lands $150M upfront from Genentech

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) acquired exclusive, worldwide rights to cancer candidate NLG919 from NewLink Genetics Corp. (NASDAQ:NLNK) for $150 million up front. NewLink is eligible for more than $1 billion in milestones, plus escalating double-digit royalties, and retains co-commercialization rights in the U.S. more >>

   COMPANY NEWS

AbbVie, Shire abandon the altar

AbbVie Inc. (NYSE:ABBV) and Shire plc (LSE:SHP; NASDAQ:SHPG) on Monday agreed to terminate their proposed acquisition, less than a week after the pharma said it was reconsidering the deal. AbbVie must now pay Shire a $1.6 billion breakup fee, and investors still holding out hope for an eventual deal now will have to wait a year under U.K. law. more >>

FDA panel backs Novartis' secukinumab for psoriasis

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 7-0 to recommend approval of Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The PDUFA date is not disclosed; Novartis submitted the BLA in October 2013. more >>

Taiho put on Fast Track in mCRC

The Taiho Oncology Inc. subsidiary of Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) said FDA has granted Fast Track designation for its TAS-102 to treat refractory metastatic colorectal cancer (mCRC) and that the company has started a rolling NDA submission to the agency. more >>

   CLINICAL NEWS

Strong Phase II Crohn's data for Celgene

Mongersen (GED-0301) from Celgene Corp. (NASDAQ:CELG) produced clinical remission rates as high as 65.1% in a Phase II trial in 166 patients with moderate to severe Crohn's disease, according to an abstract published in advance of the United European Gastroenterology's meeting in Vienna. more >>

   FINANCIAL NEWS

HealthCare Royalty Partners closes $1.5B fund

HealthCare Royalty Partners closed its third fund, HealthCare Royalty Partners III, at $1.5 billion, which the firm said exceeded its original target by over 75%. more >>

PureTech raises $55M

Science and technology development firm PureTech Ventures (Boston, Mass.) raised $55 million from Invesco Perpetual and other investors including endowments, angels and pharma companies. The funding builds on about $32 million in prior investments, according to CEO Daphne Zohar. more >>

Viamet withdraws IPO

Viamet Pharmaceuticals Inc. (Durham, N.C.) withdrew its proposed IPO on NASDAQ. The company did not provide a reason in its SEC filing and did not respond to inquiries. In July, the infectious disease play filed to raise up to $75 million in an offering underwritten by Piper Jaffray; Wells Fargo and Stifel. more >>

DBV sets terms for dual listing

DBV Technologies (Euronext:DBV) finalized the details of its planned global offering of shares that will include a dual-listing of ADSs on NASDAQ. more >>

   POLITICS & POLICY

U.S. calls pathogen research timeout

The White House Office of Science and Technology Policy (OSTP) and HHS announced the U.S. government has halted funding for "gain of function" (GOF) research that could increase the pathogenicity or respiratory transmission of influenza, SARS and MERS viruses. The hiatus will remain in effect while the government carries out a risk-benefit assessment and adopts a new federal policy regarding GOF research. This process is expected to end in 2015. more >>

Advertisement

BIOCENTURY, THE BERNSTEIN REPORT ON BIOBUSINESS

BIOCENTURY, THE BERNSTEIN REPORT ON BIOBUSINESS
COVER STORY

Walking the toll road

Better understanding of biology and new delivery approaches are refreshing interest in TLR modulators.

STRATEGY

Guest Commentary: Paying for cures

A Guest Commentary proposes a framework to help evaluate the value of drugs and define financing options to ensure access.

PRODUCT DISCOVERY & DEVELOPMENT

Beyond knockdown

Alnylam's Phase II patisiran data are the first to validate the company's siRNA platform on a clinically meaningful endpoint.

EMERGING COMPANY PROFILE

Kesios: Reactivating apoptosis

Kesios is targeting tumor-specific NF-kappa B signaling to develop a safer treatment for multiple myeloma.

Rogne: Penetrating peptides

Rogne's topical peptide to treat mild to moderate psoriasis could be safer than topical steroids or injectable biologics.

FINANCE

Sticking with big

Why Canaan is sticking with hybrid venture model for $675M tenth fund

Bicycle pedals on

Bicycle to use £20M to move two bicycle-drug conjugates into clinic for cancer

Raising for Raze

How Atlas built Raze to explore novel mitochondrial metabolism targets in cancer

User Agreement | Terms of Use | Privacy Policy | Your California Privacy Rights | Use of Images

Advertisement